World Health Organization Issues Warning Over Severe Lack of Obesity Medications

Less than 10% of people who could benefit from GLP-1 drugs like Wegovy can access them, warns the global health agency as it issues its initial guidance on the medications.

Given over a billion people worldwide now classified as obese, it is urging more widespread and fairer access to this class of drugs.

According to projections, more than two billion will be obese by 2030 if no action is taken.

"Our new guidelines acknowledges that excess weight is a lifelong illness that can be addressed with thorough and lifelong treatment," stated WHO director-general Tedros Adhanom Ghebreyesus.

High costs, constrained manufacturing, and supply-chain constraints are key obstacles to universal access to the jabs that can help people shift substantial body mass, explains the organization.

Skinny Jab Supply Crisis

Despite the present most optimistic scenario, the production of these medications would only suffice for about 100 million people – fewer than 10% of eligible patients, as stated by the health organization.

The advice urges governments and firms to widen access, by measures like patent sharing.

The intellectual property rights on a key compound – the core ingredient of a leading brand – is due to expire in several nations in 2026.

The Way Weight-Loss Injections Operate

These medications mimick a biological compound to reduce digestion speed, curb appetite and increase satiety so individuals eat less.

People commonly begin shedding pounds after several weeks of beginning the regular doses.

Studies indicates people may see weight return a year later of stopping the treatment, when their normal hunger return.

Being carrying excess weight raises your likelihood for contracting diseases, like type 2 diabetes, heart disease, brain attack, and some cancers.

Obesity impacts people in countries worldwide and was linked to over three and a half million deaths worldwide in 2024, according to the WHO.